Taking stock of the drug industry, from the lab to the medicine chestNovember 26, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Opinion: Don't expect Novo-Catalent merger investigation to fizzle out under the new Trump administration As a former policy director of the Federal Trade Commission, I expect the agency to challenge the Novo-Catalent merger. By David Balto Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound The incoming Trump administration would have to finalize the plan, which could extend the medicines to more people but increase spending. By Rachel Cohrs Zhang STAT+ | Sarepta, Arrowhead Pharmaceuticals partner to advance RNA-based drugs in rare diseases With the Arrowhead collaboration, Sarepta is buying into a lucrative, fast-moving race to develop RNA drugs for other rare diseases. By Jason Mast Alex Hogan/ STAT STAT+ | Amgen drug leads to substantial weight loss in study, but questions remain about competitiveness The drug led to significant weight loss in a mid-stage trial, and Amgen said it was launching a Phase 3 study. By Andrew Joseph STAT+ | Roche immunotherapy fails in lung cancer study, raising questions about drug's target The company said that it was awaiting results from other trials of the drug, tiragolumab, but that it continuously reviews its programs. By Andrew Joseph More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments